Nasopharyngeal Carcinoma
Conditions
Keywords
FNA,EUS,retropharyngeal lymph node (RPLN),NPC
Brief summary
EUS-FNA for RPLN in NPC
Detailed description
To evaluate the safety and efficacy of a novel minimally invasive sampling technique -- fine needle aspiration (FNA) guided by endoscopic ultrasound (EUS), which aims to sample tissues from retropharyngeal lymph nodes (RPLN) for the diagnosis of patients with suspected recurrent nasopharyngeal carcinoma (NPC).
Interventions
PROCEDUREEUS-FNA for RPLN in NPC patients
An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
Sponsors
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. had undifferentiated, non-keratinizing carcinoma at the initial diagnosis (WHO, 1991 criteria) and no evidence of distant metastasis obtained before radiotherapy; 2. received regular chemotherapy with cytotoxic agents such as cisplatin, carboplatin, 5-fluorouracil, paclitaxel, etc, and coordinated with radiotherapy with standard doses (approximate 50-70 Gy) in nasopharynx and neck respectively. Within 3 months after radiotherapy, no local and distant lesions were found; 3. during regular follow-up , the enlarged RPLN was detected by MRI more than 6 months later since radiotherapy accomplished; 4. didn't receive chemotherapy radiotherapy, immunotherapy or salvage surgery from completion of radiotherapy to suspicious recurrent lesion in RPLN detected; 5. no recurrent lesion in nasopharynx was found by white light endoscopy as well as cancer cell negative in pathology by bite biopsy; 6. single lesion in RPLN, and no other recurrent or metastatic lesion was found in local region or distant organ. 7. the minimum axial diameter of RPLN was more than 5mm.
Exclusion criteria
* (1) patients with nasal stenosis; (2) patients with coagulation dysfunction; (3) patients with distant metastasis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Accuracy | Up to 24 weeks | Number of participants with cancer positive and negative |
Countries
China
Contacts
Primary ContactJian-jun Li, MD & Ph.D
Backup ContactXin-xi Zhou, MD
Outcome results
None listed